Short and long-term outcomes of endometrial cancer and atypical endometrial hyperplasia management in young women

Objecitve: The incidence of endometrial cancer in young women is increasing. Since survival after management is in most cases excellent, the focus on long-term patient reported outcomes (PROs) is crucial. Herein we examine the characteristics and oncological and reproductive outcomes of young women with endometrial cancer. Methods: We have identified all women under 45 years of age treated at the University Medical Centre Maribor between the years 2008–2020. Women were contacted to evaluate the endometrial cancer specific PROs using the EORTC QLQ-EN24 questionnaire. Results: Endometrial cancer and atypical endometrial hyperplasia were diagnosed in women younger than 45 years in 5.1% women and in 5.3% women respectively. Fourteen women (44%) under 45 years were eligible for fertility sparing procedures and only 6 of them (43%) opted for this approach. Women who opted for fertility sparing procedures were significantly younger (p < 0.001) with a median age of 31.0 (29–35) versus 42.5 years (34–45) in women opting for standard treatment. A significant proportion of women opting for fertility sparing treatment (67%) were nulliparous (p < 0.014) at time of diagnosis. Considering PROs, a high level of reported back/pelvic pain and tingling/numbness in the limbs was reported in our group of women. Conclusions: Young women with endometrial cancer should be offered counselling on the possibility of fertility sparing procedures. Future research should focus on long term PROs and mechanisms of improving them.

Endometrial cancer; Quality of life; Fertility sparing therapy

[1] Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. International Journal of Gynecologic Cancer. 2015; 25: 1010–1014.

[2] Lai C, Wang C, Chao A. The Clinical Management of Endometrial Cancer in Young Women. Current Obstetrics and Gynecology Reports. 2013; 2: 26–31.

[3] Peiretti M, Congiu F, Ricciardi E, Maniglio P, Mais V, Angioni S. Con-servative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women. Ecancermedicalscience. 2020; 13: 892.

[4] Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takemoto T, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reproductive Biology and Endocrinology. 2016; 14: 2.

[5] Maggiore ULR, Khamisy-Farah R, Bragazzi NL, Bogani G, Martinelli F, Lopez S, et al. Fertility-sparing treatment of patients with endometrial cancer: A review of the literature. Journal of clinical medicine. 2021; 10: 4784.

[6] Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA: A Cancer Journal for Clinicians. 1999; 49: 33–64.

[7] Šegedin B, Merlo S, Smrkolj Š, Bebar S, Blatnik A, Cerar O, et al. Priporočila za obravnavo bolnic z rakom materničnega telesa Reccomendations for diagnosis, treatment and follow-up of patients with endometrial carcinoma. Onkologija. 2018; 22: 96–114.

[8] Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstetrics and Gynecology. 1984; 64: 417–420.

[9] Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstetrics and Gynecology. 1981; 57: 699–704.

[10] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[11] Emons G, Beckmann MW, Schmidt D, Mallmann P. New who Classifi-cation of Endometrial Hyperplasias. Geburtshilfe Und Frauenheilkunde. 2019; 75: 135–136.

[12] Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction. 2007; 22: 1953–1958.

[13] Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, et al. Management of endometrial cancer: issues and controversies. European Journal of Gynaecological Oncology. 2016; 37: 6–12.

[14] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer. 2021; 31: 12–39.

[15] Shisler R, Sinnott JA, Wang V, Hebert C, Salani R, Felix AS. Life after endometrial cancer: a systematic review of patient-reported outcomes. Gynecologic Oncology. 2018; 148: 403–413.

[16] Lewin SN. Revised FIGO staging system for endometrial cancer. Clinical Obstetrics and Gynecology. 2011; 54: 215–218.

[17] Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB, et al. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). European Journal of Cancer. 2011; 47: 183–190.

[18] Knez J, Mahdawi LA, Takač I, Sobočan M. The perspectives of fertility preservation in women with endometrial cancer. Cancers. 2021; 13: 602.

[19] Maggiore ULR, Martinelli F, Dondi G, Bogani G, Chiappa V, Evangelista MT, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: A retrospective study. Journal of Gynecologic Oncology. 2019; 30: e57.

[20] Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. American Journal of Obstetrics and Gynecology. 2019; 221: 474.e1–474.e11.

[21] Novikova OV, Nosov VB, Panov VA, Novikova EG, Krasnopolskaya KV, Andreeva YY, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecologic Oncology. 2021; 161: 152–159.

[22] Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women with Grade 1 Presumed Stage IA Endometrial Adenocarcinoma. International Journal of Gynecological Cancer. 2018; 28: 385–393.

[23] Park J, Seong SJ, Kim T, Kim JW, Kim SM, Bae D, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstetrics and Gynecology. 2013; 121: 136–142.

[24] Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gyneco-logic Oncology. 2012; 125: 477–482.

[25] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1094–1108.

[26] Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecologic Oncology. 2019; 153: 487–495.

[27] Son J, Carr C, Yao M, Radeva M, Priyadarshini A, Marquard J, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. International Journal of Gynecologic Cancer. 2020; 30: 631–639.

[28] Buchanan A, Roddy M, Badr H. Patient-reported outcomes of non-pharmacological interventions for endometrial cancer survivors: a systematic review. Journal of Cancer Survivorship. 2021; 15: 526–535.

[29] Hubbs JL, Dickson Michelson EL, Vogel RI, Rivard CL, Teoh DGK, Geller MA. Sexual quality of life after the treatment of gynecologic cancer: what women want. Supportive Care in Cancer. 2019; 27: 4649–4654.